Sumitomo Dainippon Pharma, Dai-ichi Life ans SBI all invested in a $17.7m round for robotics devloper Meltin MMI, after a $2.1m series A last year.
Japan-based robotics and medical device developer Meltin MMI has secured $17.7m in funding from investors including pharmaceutical company Sumitomo Dainippon Pharma and insurance provider Dai-ichi Life.
SBI Investment, a venture capital subsidiary of financial services firm SBI Group, also participated in the round.
Founded in 2013, Meltin is developing an avatar robot called Meltant which uses bio-signal processing and robotics technology to precisely replicate the movements of its human controllers.
The company emerged from an incubator owned by University of…
